Evidence map›Paper›PMID 39886538›Full record

ArticleRheumatology advances in practice2025

Challenges in the transition of care for rare connective tissue diseases: results from the 2023 ERN ReCONNET Transition of Care Task Force survey.

Edoardo Marrani, Mojca Zajc Avramovic, Diana Marinello, Rosaria Talarico, Chiara Baldini, Eva Collado-González, João Eurico Fonseca, Linda Schraven, Filipa Oliveira Ramos, Paola Triggianese and 4 more

Abstract read
In one paragraph

Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Edoardo MarraniRheumatology Unit, ERN ReCONNET Center, IRCCS Meyer Children's Hospital, Firenze, Italy.ORCID https://orcid.org/0000-0002-0346-3268
Mojca Zajc AvramovicDepartment of Allergology, Rheumatology and Clinical Immunology, Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Diana MarinelloRheumatology Unit, ERN ReCONNET Center, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Rosaria TalaricoRheumatology Unit, ERN ReCONNET Center, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.ORCID https://orcid.org/0000-0003-4268-9611
Chiara BaldiniRheumatology Unit, ERN ReCONNET Center, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.ORCID https://orcid.org/0000-0002-4454-1824
Eva Collado-GonzálezAsociación Nacional del Síndrome de Ehlers-Danlos e Hiperlaxitud, Murcia, Spain.
João Eurico FonsecaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, ULS Santa Maria, Lisbon, Portugal.
Linda SchravenFederation of European Scleroderma Associations, Saint Maur, Belgium.
Filipa Oliveira RamosUnidade de Reumatologia Pediátrica, Hospital Universitário Santa Maria, ULS Santa Maria, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0001-7132-8909
Paola TriggianeseDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Arjan VissinkDepartment of Oral and Maxillofacial Surgery, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0003-2581-4361
Marta MoscaRheumatology Unit, ERN ReCONNET Center, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Tadej AvcinDepartment of Allergology, Rheumatology and Clinical Immunology, Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Gabriele SimoniniRheumatology Unit, ERN ReCONNET Center, IRCCS Meyer Children's Hospital, Firenze, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Two different European Reference Networks cover CTDs with paediatric onset, the European Reference Network on Rare and Complex Connective Tissue Diseases (ERN ReCONNET) and the European Reference Network on Rare Immunological Disorders (ERN RITA). The transition of care is a significant focus, with ReCONNET centres actively addressing this through updated programs. Despite these efforts, challenges persist. We aimed to inventory transitional care programs for rare CTDs across Europe. Methods: In April 2023, the ERN ReCONNET Transition of Care Task Force, consisting of expert clinicians, patient advocates and coordination team members, created a survey to assess transitional care practices. The survey was distributed to ERN ReCONNET and ERN RITA centres and responses received by 15 March 2024 were analysed. Results: A total of 67 responses from 59 centres across 20 European countries were collected. Paediatric rheumatologists typically initiated the transition process (49% of centres). Twenty centres had joint clinics. Despite positive self-assessments of transitional programs, significant limitations were noted. Transition policies varied, with only 40% of centres having a formal standardized policy and less than half of the centres adhering to available transition of care guidelines. Transfer readiness was evaluated using validated questionnaires in 13% of centres, while 29% transitioned patients based solely on age without any readiness assessments. The main challenges included finding adult-oriented centres and the lack of guidelines or engagement from adult centres. Adult healthcare providers also noted a lack of training in adolescent medicine. Conclusion: The survey highlighted diverse transition practices and resources across centres, with challenges in readiness evaluation and the use of guidelines. Despite these obstacles, respondents rated ongoing transition processes positively. Enhancing patient perspectives in the transition process is crucial to meet their needs during this critical phase.

Indexed as

connective tissue diseasepaediatric rheumatologytransitional caretransition of care

Identifiers

PMID39886538
PMCPMC11780841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.